Tags

Type your tag names separated by a space and hit enter

Comparison of 5-year survival after acute myocardial infarction using angiotensin-converting enzyme inhibitor versus angiotensin II receptor blocker.
Am J Cardiol. 2014 Jul 01; 114(1):1-8.AJ

Abstract

Few studies have investigated whether angiotensin II receptor blocker (ARB) is a practical alternative to angiotensin-converting enzyme inhibitor (ACEI) for long-term use after acute myocardial infarction (AMI) in real-world practice in the percutaneous coronary intervention era. We compared 5-year survival benefits of ACEI and ARB in patients with AMI registered in the Osaka Acute Coronary Insufficiency Study. Study subjects were divided into 3 groups: ACEI (n = 4,425), ARB (n = 2,158), or patients without either drug (n = 2,442). A total of 661 deaths were recorded. Cox regression analysis revealed that treatment with either ACEI or ARB was associated with reduced 5-year mortality (adjusted hazard ratio [HR] 0.70, 95% confidence interval [CI] 0.58 to 0.83, p <0.001 and HR 0.79, 95% CI 0.64 to 0.98, p = 0.03, respectively). However, Kaplan-Meier estimates and Cox regression analyses based on propensity score revealed that ACEI was associated with better survival than ARB from 2 to 5 years after survival discharge (adjusted HR 0.53, 95% CI 0.38 to 0.74, p <0.001). These findings were confirmed in a propensity score-matched population. In conclusion, treatment with ACEI was associated with better 5-year survival after AMI.

Authors+Show Affiliations

Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Suita, Japan.Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Suita, Japan; Department of Advanced Cardiovascular Therapeutics, Osaka University Graduate School of Medicine, Suita, Japan; Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan. Electronic address: sakatayk@cardio.med.tohoku.ac.jp.Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Suita, Japan.Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Suita, Japan.Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Suita, Japan.Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Suita, Japan.Department of Biomedical Statistics, Osaka University Graduate School of Medicine, Suita, Japan.Division of Cardiology, Osaka Rosai Hospital, Sakai, Japan.School of Human Welfare Studies, Kwansei Gakuin University, Nishinomiya, Japan.Division of Environmental Medicine and Population Sciences, Department of Social and Environmental Medicine, Osaka University Graduate School of Medicine, Suita, Japan.Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Suita, Japan; Department of Advanced Cardiovascular Therapeutics, Osaka University Graduate School of Medicine, Suita, Japan.Department of Biomedical Statistics, Osaka University Graduate School of Medicine, Suita, Japan.Osaka Prefectural Hospital Organization, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan.Department of Cardiovascular Medicine, The University of Tokyo Graduate School of Medicine, Tokyo, Japan.No affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Multicenter Study
Observational Study
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

24819900

Citation

Hara, Masahiko, et al. "Comparison of 5-year Survival After Acute Myocardial Infarction Using Angiotensin-converting Enzyme Inhibitor Versus Angiotensin II Receptor Blocker." The American Journal of Cardiology, vol. 114, no. 1, 2014, pp. 1-8.
Hara M, Sakata Y, Nakatani D, et al. Comparison of 5-year survival after acute myocardial infarction using angiotensin-converting enzyme inhibitor versus angiotensin II receptor blocker. Am J Cardiol. 2014;114(1):1-8.
Hara, M., Sakata, Y., Nakatani, D., Suna, S., Usami, M., Matsumoto, S., Sugitani, T., Nishino, M., Sato, H., Kitamura, T., Nanto, S., Hamasaki, T., Hori, M., & Komuro, I. (2014). Comparison of 5-year survival after acute myocardial infarction using angiotensin-converting enzyme inhibitor versus angiotensin II receptor blocker. The American Journal of Cardiology, 114(1), 1-8. https://doi.org/10.1016/j.amjcard.2014.03.055
Hara M, et al. Comparison of 5-year Survival After Acute Myocardial Infarction Using Angiotensin-converting Enzyme Inhibitor Versus Angiotensin II Receptor Blocker. Am J Cardiol. 2014 Jul 1;114(1):1-8. PubMed PMID: 24819900.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Comparison of 5-year survival after acute myocardial infarction using angiotensin-converting enzyme inhibitor versus angiotensin II receptor blocker. AU - Hara,Masahiko, AU - Sakata,Yasuhiko, AU - Nakatani,Daisaku, AU - Suna,Shinichiro, AU - Usami,Masaya, AU - Matsumoto,Sen, AU - Sugitani,Toshifumi, AU - Nishino,Masami, AU - Sato,Hiroshi, AU - Kitamura,Tetsuhisa, AU - Nanto,Shinsuke, AU - Hamasaki,Toshimitsu, AU - Hori,Masatsugu, AU - Komuro,Issei, AU - ,, Y1 - 2014/04/18/ PY - 2014/02/22/received PY - 2014/03/25/revised PY - 2014/03/25/accepted PY - 2014/5/14/entrez PY - 2014/5/14/pubmed PY - 2014/8/1/medline SP - 1 EP - 8 JF - The American journal of cardiology JO - Am J Cardiol VL - 114 IS - 1 N2 - Few studies have investigated whether angiotensin II receptor blocker (ARB) is a practical alternative to angiotensin-converting enzyme inhibitor (ACEI) for long-term use after acute myocardial infarction (AMI) in real-world practice in the percutaneous coronary intervention era. We compared 5-year survival benefits of ACEI and ARB in patients with AMI registered in the Osaka Acute Coronary Insufficiency Study. Study subjects were divided into 3 groups: ACEI (n = 4,425), ARB (n = 2,158), or patients without either drug (n = 2,442). A total of 661 deaths were recorded. Cox regression analysis revealed that treatment with either ACEI or ARB was associated with reduced 5-year mortality (adjusted hazard ratio [HR] 0.70, 95% confidence interval [CI] 0.58 to 0.83, p <0.001 and HR 0.79, 95% CI 0.64 to 0.98, p = 0.03, respectively). However, Kaplan-Meier estimates and Cox regression analyses based on propensity score revealed that ACEI was associated with better survival than ARB from 2 to 5 years after survival discharge (adjusted HR 0.53, 95% CI 0.38 to 0.74, p <0.001). These findings were confirmed in a propensity score-matched population. In conclusion, treatment with ACEI was associated with better 5-year survival after AMI. SN - 1879-1913 UR - https://www.unboundmedicine.com/medline/citation/24819900/Comparison_of_5_year_survival_after_acute_myocardial_infarction_using_angiotensin_converting_enzyme_inhibitor_versus_angiotensin_II_receptor_blocker_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0002-9149(14)00944-8 DB - PRIME DP - Unbound Medicine ER -